Mitsubishi UFJ Asset Management Co. Ltd. Boosts Stock Position in Merck & Co., Inc. $MRK

Key Points

• Mitsubishi UFJ Asset Management increased its Merck stake by 7% in the second quarter, adding 402,011 shares to own 6.18 million shares valued at approximately $794.6 million. Institutional investors collectively hold 76.07% of MRK.
• Merck reported better-than-expected quarterly results, with revenue of $16.61 billion and EPS of $(0.13), while revenue rose 5.1% year over year. The company also declared a quarterly dividend of $0.85, equivalent to a 2.2% annual yield.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $147.60, although several analysts recently raised targets as high as $180. Merck shares have rallied sharply, while insider selling and the need for successful pipeline and regulatory outcomes present risks.

Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 7.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,184,340 shares of the company's stock after buying an additional 402,011 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.25% of Merck & Co., Inc. worth $794,577,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. State Street Corp raised its position in Merck & Co., Inc. by 1.6% during the fourth quarter. State Street Corp now owns 120,040,168 shares of the company's stock worth $12,737,504,000 after acquiring an additional 1,859,990 shares during the period. Wellington Management Group LLP increased its stake in shares of Merck & Co., Inc. by 14.8% during the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock worth $9,098,196,000 after purchasing an additional 11,156,354 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Merck & Co., Inc. by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company's stock worth $6,307,572,000 after purchasing an additional 249,110 shares during the last quarter. Morgan Stanley lifted its stake in Merck & Co., Inc. by 0.8% in the 4th quarter. Morgan Stanley now owns 44,946,021 shares of the company's stock valued at $4,731,018,000 after buying an additional 359,486 shares in the last quarter. Finally, Norges Bank acquired a new stake in Merck & Co., Inc. in the 4th quarter worth about $3,997,933,000. Institutional investors and hedge funds own 76.07% of the company's stock.

Merck & Co., Inc. Trading Up 3.9%

Shares of MRK opened at $156.54 on Wednesday. Merck & Co., Inc. has a 12-month low of $77.58 and a 12-month high of $156.92. The firm has a market capitalization of $386.22 billion, a P/E ratio of 125.23, a P/E/G ratio of 6.32 and a beta of 0.19. The firm has a 50-day moving average price of $129.64 and a 200 day moving average price of $121.80. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the previous year, the firm earned $2.13 earnings per share. Merck & Co., Inc.'s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Sell-side analysts forecast that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.2%. Merck & Co., Inc.'s dividend payout ratio is currently 272.00%.

Analysts Set New Price Targets

MRK has been the subject of a number of research analyst reports. Argus increased their target price on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a "buy" rating in a report on Tuesday. Wolfe Research increased their price objective on Merck & Co., Inc. from $155.00 to $180.00 and gave the company an "outperform" rating in a research note on Tuesday. Bank of America lifted their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a "buy" rating in a research note on Tuesday, June 30th. BMO Capital Markets upped their target price on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the stock an "outperform" rating in a report on Thursday, August 20th. Finally, CICC Research initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an "outperform" rating and a $138.00 price target on the stock. Fifteen research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $147.60.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive topline INTerpath-001 results strengthened expectations that the vaccine could extend KEYTRUDA’s growth runway and create a potentially important new oncology franchise. Merck Surges on a Melanoma Win
• Positive Sentiment: Analysts raised their valuation expectations: Wolfe Research increased its price target to $180 and assigned an “outperform” rating, while Argus raised its target to $170 and reiterated a “buy” rating. Wolfe Research Price Target
• Positive Sentiment: Investors are also anticipating a concentrated series of regulatory decisions and clinical readouts this fall, which could produce additional upside if Merck’s pipeline delivers. What Would It Take to Get MRK Stock to $200?
• Neutral Sentiment: The cancer-vaccine opportunity remains early. The available evidence is limited, and potential barriers include manufacturing complexity, cost, patient selection, and the need for regulatory review and broader clinical validation. How the Merck/Moderna Cancer Vaccine Works
• Negative Sentiment: After the recent rally, MRK is trading near or above several analysts’ prior targets, leaving less room for disappointment and making future gains increasingly dependent on successful trial results, FDA decisions, and evidence that the post-KEYTRUDA growth strategy can scale.

Insider Buying and Selling

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the firm's stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the sale, the executive vice president owned 45,509 shares of the company's stock, valued at $6,073,631.14. This trade represents a 63.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Michael Williams sold 52,847 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares in the company, valued at $4,084,069.32. This represents a 62.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 in the last ninety days. Company insiders own 0.17% of the company's stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source